218 related articles for article (PubMed ID: 12480707)
1. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells.
Heidenreich O; Krauter J; Riehle H; Hadwiger P; John M; Heil G; Vornlocher HP; Nordheim A
Blood; 2003 Apr; 101(8):3157-63. PubMed ID: 12480707
[TBL] [Abstract][Full Text] [Related]
2. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
Kasashima K; Sakota E; Kozu T
Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
[TBL] [Abstract][Full Text] [Related]
3. siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts.
Dunne J; Cullmann C; Ritter M; Soria NM; Drescher B; Debernardi S; Skoulakis S; Hartmann O; Krause M; Krauter J; Neubauer A; Young BD; Heidenreich O
Oncogene; 2006 Oct; 25(45):6067-78. PubMed ID: 16652140
[TBL] [Abstract][Full Text] [Related]
4. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon.
Shimizu K; Kitabayashi I; Kamada N; Abe T; Maseki N; Suzukawa K; Ohki M
Blood; 2000 Jul; 96(1):288-96. PubMed ID: 10891464
[TBL] [Abstract][Full Text] [Related]
5. UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8.
Fukuyama T; Kitamura T; Kozu T
Int J Hematol; 2022 May; 115(5):686-693. PubMed ID: 35152350
[TBL] [Abstract][Full Text] [Related]
6. In vitro catalytic activities of DNA/RNA chimeric hammerhead ribozymes against AML1-MTG8 mRNA, a fused gene transcript in acute myeloid leukemia with t(8;21).
Kozu T; Sueoka E; Okabe S; Sueoka N; Komori A; Fujiki H
Biochimie; 1996; 78(11-12):1067-73. PubMed ID: 9150886
[TBL] [Abstract][Full Text] [Related]
7. Leukemic fusion genes MLL/AF4 and AML1/MTG8 support leukemic self-renewal by controlling expression of the telomerase subunit TERT.
Gessner A; Thomas M; Castro PG; Büchler L; Scholz A; Brümmendorf TH; Soria NM; Vormoor J; Greil J; Heidenreich O
Leukemia; 2010 Oct; 24(10):1751-9. PubMed ID: 20686504
[TBL] [Abstract][Full Text] [Related]
8. Designing of chimeric DNA/RNA hammerhead ribozymes to be targeted against AML1/MTG8 mRNA.
Kozu T; Sueoka E; Okabe S; Sueoka N; Komori A; Fujiki H
J Cancer Res Clin Oncol; 1996; 122(4):254-6. PubMed ID: 8601580
[TBL] [Abstract][Full Text] [Related]
9. Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF.
Shimada H; Ichikawa H; Nakamura S; Katsu R; Iwasa M; Kitabayashi I; Ohki M
Blood; 2000 Jul; 96(2):655-63. PubMed ID: 10887131
[TBL] [Abstract][Full Text] [Related]
10. Functional G-CSF pathways in t(8;21) leukemic cells allow for differentiation induction and degradation of AML1-ETO.
Da Silva N; Meyer-Monard S; Menot ML; Parrado A; Lebel A; Balitrand N; Fenaux P; Micléa JM; Rousselot P; Degos L; Dombret H; Chomienne C
Hematol J; 2000; 1(5):316-28. PubMed ID: 11920209
[TBL] [Abstract][Full Text] [Related]
11. Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis.
Rhoades KL; Hetherington CJ; Rowley JD; Hiebert SW; Nucifora G; Tenen DG; Zhang DE
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11895-900. PubMed ID: 8876234
[TBL] [Abstract][Full Text] [Related]
12. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
[TBL] [Abstract][Full Text] [Related]
13. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia.
Kondo M; Kudo K; Kimura H; Inaba J; Kato K; Kojima S; Matsuyama T; Horibe K
Leuk Res; 2000 Nov; 24(11):951-6. PubMed ID: 11086178
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of minimal residual disease by quantitative reverse transcriptase-polymerase chain reaction for AML1-MTG8 transcripts in AML-M2 with t(8; 21).
Tobal K; Yin JA
Blood; 1996 Nov; 88(10):3704-9. PubMed ID: 8916934
[TBL] [Abstract][Full Text] [Related]
15. The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript.
Miyoshi H; Kozu T; Shimizu K; Enomoto K; Maseki N; Kaneko Y; Kamada N; Ohki M
EMBO J; 1993 Jul; 12(7):2715-21. PubMed ID: 8334990
[TBL] [Abstract][Full Text] [Related]
16. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
Lo Coco F; Pisegna S; Diverio D
Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
[TBL] [Abstract][Full Text] [Related]
17. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia.
Miyamoto T; Nagafuji K; Akashi K; Harada M; Kyo T; Akashi T; Takenaka K; Mizuno S; Gondo H; Okamura T; Dohy H; Niho Y
Blood; 1996 Jun; 87(11):4789-96. PubMed ID: 8639850
[TBL] [Abstract][Full Text] [Related]
18. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
[TBL] [Abstract][Full Text] [Related]
19. Induction of apoptosis in myeloid leukaemic cells by ribozymes targeted against AML1/MTG8.
Matsushita H; Kizaki M; Kobayashi H; Muto A; Ikeda Y
Br J Cancer; 1999 Mar; 79(9-10):1325-31. PubMed ID: 10188872
[TBL] [Abstract][Full Text] [Related]
20. A distinct epigenetic signature at targets of a leukemia protein.
Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
